Intradetrusor Onabotulinumtoxin A (Botox) at the Time of Transurethral Resection of the Prostate or Transurethral Waterjet Ablation of the Prostate for Mixed Lower Urinary Tract Symptoms

Benaroya Research Institute20 enrolled

Overview

Patients with longstanding obstructive lower urinary tract symptoms (LUTS) due to benign prostatic hypertrophy (BPH) can also develop symptoms of overactive bladder syndrome (OAB). Transurethral resection of the prostate (TURP) and Transurethral Waterjet Ablation of the Prostate (Aquablation) are amongst the gold standard surgical treatments for BPH. However, in the immediate post-operative period, TURP and Aquablation can also include OAB-like symptoms, including urinary frequency and urgency. For men with baseline OAB symptoms, this initial worsening of symptoms can be distressing. Botox is an FDA approved medication with on-label indications to treat overactive bladder. The purpose of this study is to evaluate the outcomes of men who have Botox concurrent with their TURP or Aquablation.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Benign Prostatic Hypertrophy (BPH)Lower Urinary Track Symptoms

Interventions

Survey using a questionnaire.

* 1 week post-operative visit for: trial of void, to assess for rates of postoperative urinary retention. * 4 and 12 week post-operative visits for: post void residual assessment via bladder scan, AUA symptom score, PGI-I, UDI-6, and VM Post Procedure questionnaires will be administered * Hospitalization readmission rates, urinary retention episodes will also be recorded.

Eligibility

Sex: MALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Male \>= 18 years of age and being scheduled to undergo TURP or Aquablation and Botox procedure. 2. Written informed consent obtained from subject and ability for subject to comply with the requirements of the study. Exclusion Criteria: 3. Non-English speaking 4. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data. 5. History of receiving Botox in the bladder, within the previous 12 months.

Outcomes

Primary Outcomes

To identify whether concurrent Botox and TURP or Aquablation are effective at reducing post-operative irritative voiding symptoms.

This will be measured using Postoperative Urinary Retention (POUR): At 1 week post-operative visit for trial of void to assess for rates of postoperative urinary retention. At 4 and 12 week post-operative visits for post void residual assessment

Time frame: 4 months

Secondary Outcomes

To identify whether concurrent Botox and TURP or Aquablation lead to longer hospitalizations.

Analyzing admission data to determine if there are any changes to the hospital admission rates.

Time frame: 4 months

To identify whether concurrent Botox and TURP or Aquablation lead to higher rates of urinary retention.

Analyzing admission data to determine if there are any changes to the urinary retention episodes.

Time frame: 4 months

Intradetrusor Onabotulinumtoxin A (Botox) at the Time of Transurethral Resection of the Prostate or Transurethral Waterjet Ablation of the Prostate for Mixed Lower Urinary Tract Symptoms

Overview

Conditions

Interventions

Eligibility

Locations (1)

Outcomes

Primary Outcomes

Secondary Outcomes

Central Contacts